iBio Stock Forecast, Price & News

iBio (NYSEAMERICAN:IBIO) Frequently Asked Questions

Is iBio a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" iBio stock.
View analyst ratings for iBio or view top-rated stocks.

What stocks does MarketBeat like better than iBio?

Wall Street analysts have given iBio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but iBio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is iBio's next earnings date?

iBio is scheduled to release its next quarterly earnings announcement on Monday, September 27th 2021.
View our earnings forecast for iBio.

How were iBio's earnings last quarter?

iBio, Inc. (NYSEAMERICAN:IBIO) posted its earnings results on Monday, May, 17th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The biotechnology company had revenue of $0.77 million for the quarter. iBio had a negative net margin of 895.37% and a negative trailing twelve-month return on equity of 30.81%.
View iBio's earnings history.

When did iBio's stock split? How did iBio's stock split work?

iBio shares reverse split on the morning of Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 8th 2018. An investor that had 100 shares of iBio stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for IBIO?

2 analysts have issued 12-month target prices for iBio's shares. Their forecasts range from $2.00 to $3.00. On average, they anticipate iBio's stock price to reach $2.50 in the next year. This suggests a possible upside of 114.6% from the stock's current price.
View analysts' price targets for iBio or view top-rated stocks among Wall Street analysts.

Who are iBio's key executives?

iBio's management team includes the following people:

• Thomas F. Isett, Executive Chairman, President & CEO
• Randy J. Maddux, Chief Operating Officer
• Robert M. Lutz, Chief Financial, Accounting & Business Officer
• Martin B. Brenner, Chief Scientific Officer
• Robert B. Kay, Secretary, Treasurer & Director

Who are some of iBio's key competitors?

Some companies that are related to iBio include IDEAYA Biosciences (IDYA), CannTrust (CNTTF), Nkarta (NKTX), FibroGen (FGEN), Prometheus Biosciences (RXDX), Keros Therapeutics (KROS), Stoke Therapeutics (STOK), Vanda Pharmaceuticals (VNDA), Praxis Precision Medicines (PRAX), Janux Therapeutics (JANX), ORIC Pharmaceuticals (ORIC), Syndax Pharmaceuticals (SNDX), Omeros (OMER), Amphastar Pharmaceuticals (AMPH) and Celularity (CELU).
View all of IBIO's competitors.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia (NOK) and Moderna (MRNA).

What is iBio's stock symbol?

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

Who are iBio's major shareholders?

iBio's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.14%), Vanguard Group Inc. (4.80%), State Street Corp (1.77%), Geode Capital Management LLC (1.64%), Northern Trust Corp (0.92%) and Susquehanna International Group LLP (0.00%). Company insiders that own iBio stock include Eastern Capital Ltd, James P Mullaney and Robert L Erwin.
View institutional ownership trends for iBio.

Which major investors are selling iBio stock?

IBIO stock was sold by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., JPMorgan Chase & Co., Bank of America Corp DE, Northern Trust Corp, Millennium Management LLC, Vanguard Group Inc., Price T Rowe Associates Inc. MD, and Invesco Ltd..
View insider buying and selling activity for iBio or view top insider-selling stocks.

Which major investors are buying iBio stock?

IBIO stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Susquehanna International Group LLP, Squarepoint Ops LLC, Nuveen Asset Management LLC, Geode Capital Management LLC, Marshall Wace LLP, Marshall Wace LLP, and Man Group plc.
View insider buying and selling activity for iBio or or view top insider-buying stocks.

How do I buy shares of iBio?

Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iBio's stock price today?

One share of IBIO stock can currently be purchased for approximately $1.17.

How much money does iBio make?

iBio has a market capitalization of $253.80 million and generates $1.64 million in revenue each year. The biotechnology company earns $-16,440,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

How many employees does iBio have?

iBio employs 47 workers across the globe.

What is iBio's official website?

The official website for iBio is www.ibioinc.com.

Where are iBio's headquarters?

iBio is headquartered at 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States.

How can I contact iBio?

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at (302) 355-0650 or via email at [email protected].